Life Technologies has signed a collaborative partnership with the Structural Genomics Consortium and other big pharma companies, and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.
The recombinant antibodies are being developed by Life Technologies in partnership with the SGC, which comprises a network of more than 200 scientists from the University of Toronto and Oxford University, as well as six big pharma companies, which include AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer and Takeda.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity